Captor Therapeutics Spolka Akcyjna

WSE:CTX 株式レポート

時価総額:zł223.4m

Captor Therapeutics Spolka Akcyjna マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Tom Shepherd

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間3.8yrs
CEOの所有権1.3%
経営陣の平均在職期間データなし
取締役会の平均在任期間2.8yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation

Jul 13
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation

We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth

Mar 10
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth

We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn

Oct 03
We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn

Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation

Mar 13
Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation

Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth

Jun 15
Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth

CEO(最高経営責任者

Tom Shepherd

3.8yrs

在職期間

Dr. Thomas Shepherd, Ph D also known as Tom, is Chief Executive Officer at Captor Therapeutics spolka akcyjna and serves as Executive Chairman of Captor Therapeutics's Swiss affiliate, with responsibility...


取締役

名称ポジション在職期間報酬所有権
Charles Kunsch
Independent Member of the Supervisory Board1.6yrsデータなしデータなし
Andrew Saunders
Chief Medical Officer1.8yrsデータなしデータなし
Pawel Holsten
Chairman of the Supervisory Board6.3yrsデータなし7.72%
PLN 17.2m
Robert Florczykowski
Independent Member of the Supervisory Board2.8yrsデータなしデータなし
Krzysztof Samotij
Independent Member of the Supervisory Boardno dataデータなし0.13%
PLN 298.0k
Maciej Wroblewski
Member of the Supervisory Board3.7yrsデータなし0.13%
PLN 298.0k

2.8yrs

平均在職期間

経験豊富なボード: CTXの 取締役会経験豊富 ではない ( 2.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。